Since older patients are increasingly treated with these anti-ErbB2 drugs, and trastuzumab is widely used for its efficient therapeutic effects on metastatic cancer thus prolonging even more patient's survival in last decades, a different approach is needed to guarantee the survival of treated patients to avoid that women recovered from cancer paradoxically die for heart failure. The gene discussed is ERBB2; the disease is metastatic malignant neoplasm.